Clinical Outcome of Beta-Tricalcium Phosphate Use for Bone Defects after Operative Treatment of Benign Tumors

BACKGROUND: We investigated the clinical outcome in patients whose cavitary bone defects were treated with beta-tricalcium phosphate (β-TCP) after surgical removal of benign tumors. METHODS: Between March 2015 and December 2015, 20 patients who underwent operation for bone tumors were enrolled into this study and prospectively followed up for a median period of 28.1 months. RESULTS: When the radiographic sign of complete resorption was defined as greater than 50% resorption of the allograft material accompanied by bone remodeling until 12 months, 55% of patients had complete resorption. Positive correlation between the filling volume and time needed for complete resorption was not found (p = 0.184). CONCLUSIONS: Purified β-TCP could be a suitable choice as a bone graft substitute after the removal of benign bone tumors.